Literature DB >> 17208429

The oncogenic roles of p53 mutants in mouse models.

Guillermina Lozano1.   

Abstract

Tumors associated with p53 usually contain missense mutations in the p53 tumor suppressor gene rather than deletions of p53, suggesting a growth advantage for cells with missense mutations. The oncogenic roles of p53 mutants have been examined extensively in cell lines. Mouse models that inherit p53 mutations expressed at physiological levels have now been generated to examine the activities of mutant p53 upon tumorigenesis in vivo. Mice with p53 mutations develop tumor spectrums and metastatic phenotypes different from those of mice with a p53-null allele. Embryo fibroblasts with mutant p53 also show increased proliferative and transformation properties. One mechanism for this gain-of-function potential is the inhibition of function of the p53 family members p63 and p73.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17208429     DOI: 10.1016/j.gde.2006.12.003

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  39 in total

1.  Cross-talk between T-Ag presence and pRb family and p53/p73 signaling in mouse and human medulloblastoma.

Authors:  Valentina Caracciolo; Marcella Macaluso; Luca D'Agostino; Micaela Montanari; Jonathan Scheff; Krzysztof Reiss; Kamel Khalili; Antonio Giordano
Journal:  J Cell Biochem       Date:  2010-05       Impact factor: 4.429

2.  Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.

Authors:  Yongxing Wang; Young-Ah Suh; Maren Y Fuller; James G Jackson; Shunbin Xiong; Tamara Terzian; Alfonso Quintás-Cardama; James A Bankson; Adel K El-Naggar; Guillermina Lozano
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

3.  Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia.

Authors:  Hong Shi; Si-jie Tan; Hua Zhong; Wenwei Hu; Arnold Levine; Chun-jie Xiao; Yi Peng; Xue-bin Qi; Wei-hua Shou; Run-lin Z Ma; Yi Li; Bing Su; Xin Lu
Journal:  Am J Hum Genet       Date:  2009-04-02       Impact factor: 11.025

4.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

5.  A planarian p53 homolog regulates proliferation and self-renewal in adult stem cell lineages.

Authors:  Bret J Pearson; Alejandro Sánchez Alvarado
Journal:  Development       Date:  2010-01       Impact factor: 6.868

6.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

Review 7.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

Review 8.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

Review 9.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

10.  p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.

Authors:  Shu-Ping Wang; Wen-Lung Wang; Yih-Leong Chang; Chen-Tu Wu; Yu-Chih Chao; Shih-Han Kao; Ang Yuan; Chung-Wu Lin; Shuenn-Chen Yang; Wing-Kai Chan; Ker-Chau Li; Tse-Ming Hong; Pan-Chyr Yang
Journal:  Nat Cell Biol       Date:  2009-05-17       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.